HSP105 peptide-pulsed dendritic cell vaccine - Medinet

Drug Profile

HSP105 peptide-pulsed dendritic cell vaccine - Medinet

Alternative Names: Cytotoxic T-lymphocyte stimulants-based cancer vaccine - Medinet; Dendritic cell-stimulated vaccine - Medinet; Heat shock protein 105 peptide-pulsed dendritic cell vaccine - Medinet; HSP105-derived cancer antigen peptide vaccine - Medinet

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medinet
  • Developer Medinet; University of Tokyo
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer
  • No development reported Renal cell carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Renal-cell-carcinoma(Combination therapy, Late-stage disease) in Japan (Parenteral)
  • 15 Nov 2011 Phase-II clinical trials in Cancer (late-stage disease) in Japan (Parenteral) (UMIN000006730)
  • 31 Mar 2009 Medinet acquires a licence to patents for HSP105-derived peptides from Kumamoto Technology and Industrial Foundation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top